{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Karen L Barker, Jon Room, Ruth Knight, Susan J Dutton, Fran Toye, Jose Leal, Seamus Kent, Nicola Kenealy, Michael M Schussel, Gary Collins, David J Beard, Andrew Price, Martin Underwood, Avril Drummond, Elaine Cook & Sarah E Lamb.

Karen L Barker ^1,2,*, Jon Room ^1,2, Ruth Knight ³, Susan J Dutton ³, Fran Toye ², Jose Leal ⁴, Seamus Kent ⁴, Nicola Kenealy ¹, Michael M Schussel ³, Gary Collins ³, David J Beard ¹, Andrew Price ¹, Martin Underwood ⁵, Avril Drummond ⁶, Elaine Cook ⁷, Sarah E Lamb ^1,8

¹ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
² Physiotherapy Research Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
³ Centre for Statistics in Medicine, Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK
⁴ Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
⁵ Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
⁶ School of Health Sciences, University of Nottingham, Nottingham, UK
⁷ Patient and public involvement member, ,
⁸ School of Medicine and Health, University of Exeter, Exeter, UK
^* Corresponding author Email: karen.barker@ouh.nhs.uk

Declared competing interests of authors: Gary Collins is a member of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Commissioning Board (2017–20). Martin Underwood reports grants and personal fees from NIHR; being a member of the NIHR Journals Library Editorial Group (2016–19); personal fees from National Institute for Health and Care Excellence; non-financial support from Stryker plc (Stryker UK Ltd, Newbury, Berkshire, UK); and grants from SERCO Ltd (Hook, UK). Andrew Price reports personal fees from consultancy with Zimmer Biomet (Warsaw, IN, USA) outside the submitted work. Sarah E Lamb reports grants from the NIHR HTA programme during the conduct of the study and is a member of the following boards: HTA Additional Capacity Funding Board (2010–15), HTA Clinical Trials Board (2010–15), HTA End of Life Care and Add on Studies (2015), HTA Funding Boards Policy Group (formally Commissioning Strategy Group) (2010–15), HTA Maternal, Neonatal and Child Health Methods Group (2013–15), HTA post-board funding teleconference (Prioritisation Group members to attend) (2010–15), HTA Primary Care Themed Call board (2013–14), HTA Prioritisation Group (2014–15), and NIHR Clinical Trials Unit Standing Advisory Committee (2012–16).